Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 211 Triple Negative Breast Neoplasms 32 Inflammatory Breast Neoplasms 21 Breast Neoplasms, Male 5 Primary Breast Cancer 3 Neoplasms 3 Carcinoma, Ductal, Breast 3 Pathologic Complete Response 2 HER2-negative Breast Cancer 2 Cardiotoxicity 2 Breast Diseases 2 Women With Primary Breast Cancer 1 Unilateral HER2 Positive Breast Cancer 1 Sarcoma 1 Resectable HER2-positive Breast Cancer 1 Postoperative Complications 1 Patient Acceptance of Health Care 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Ovarian Neoplasms 1 Neutropenia 1 Neoplastic Cells, Circulating 1 Neoplasm Micrometastasis 1 Neoadjuvant Operable Breast Cancer 1 Kenny-Caffey syndrome, Type 1 1 Hormone Receptor Positive HER-2 Negative Breast Cancer 1 Her2-Positive Breast Cancer 1 HR-positive,HER2-negative Breast Cancer 1 HR+/HER2- Breast Cancer 1 HER2-negative Early Breast Cancer 1 HER2 Positive Early Breast Cancer 1

Interventions

palbociclib 1 Letrozole 1 Fluorouracil 1 Epirubicin 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neoadjuvant Operable Breast Cancer × Epirubicin × Breast × Clear all

NCT02400567 2022-03-15

NeoPAL

UNICANCER

Phase 2 Completed

Neoadjuvant Operable Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡